An extended-release formulation of tacrolimus designed for once-daily administration (LCP-TAC) is a new prolonged-release tacrolimus (TAC-PR) formulation using a drug delivery technology designed to enhance the bioavailability of drugs compared with TAC-PR. The aim of this study was to retrospectively compare de novo administration of LCP-TAC and TAC-PR for therapeutic trough levels and daily dosage during the first 30 days after first liver transplant (LT).
MeltDose Technology vs Once-Daily Prolonged Release Tacrolimus in De Novo Liver Transplant Recipients
Baccarani U.;Pravisani R.;Lorenzin D.;Cherchi V.;Baraldo M.;Risaliti A.
2019-01-01
Abstract
An extended-release formulation of tacrolimus designed for once-daily administration (LCP-TAC) is a new prolonged-release tacrolimus (TAC-PR) formulation using a drug delivery technology designed to enhance the bioavailability of drugs compared with TAC-PR. The aim of this study was to retrospectively compare de novo administration of LCP-TAC and TAC-PR for therapeutic trough levels and daily dosage during the first 30 days after first liver transplant (LT).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Meltdose in liver Baccarani Baraldo.pdf
non disponibili
Descrizione: ARTICOLO PRINCIPALE
Tipologia:
Versione Editoriale (PDF)
Licenza:
Non pubblico
Dimensione
234.84 kB
Formato
Adobe PDF
|
234.84 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
